Indivumed announces expansion into drug development and reports the formation of Ix Therapeutics
Saturday, March 20, 2021
Indivumed GmbH ("Indivumed") announced, together with Xlife Sciences AG ("Xlife Sciences"), the establishment of the Ix Therapeutics GmbH ("Ix Therapeutics") joint venture. Indivuman's expansion into target cancer discovery and drug development, bringing entirely new cancer treatment options, will initially work with Veraxa Biotech AG ("Veraxa"), whose technology for the rapid development of functional therapeutic antibodies will medicines used to fight colon and lung cancer.
"Our unique IndivuType multi-omics database, together with the AI-Advanced Data Analytics" AI platform, can discover and validate a number of new goals while putting them into a complex biological and clinical context. This unique feature significantly increases the likelihood of success in the clinical phase of drug development, "said Prof. Dr. Hartmut Juhl , CEO and Founder of Indivumed." By partnering with Xlife Sciences and using Veraxa as a unique service provider, we are now able to fund therapeutic antibody development against colorectal and lung cancer, which is another crucial step towards realizing our vision of individualizing the diagnosis and treatment of cancer and providing real personalized medical services to patients. "
The IndivuType database is the only worldwide multi-omics oncology database that integrates comprehensive clinical data from thousands of patients with whole genome sequencing and transcriptomic, proteomic and phosphoproteomic data obtained from each patient under identical, highly standardized conditions. Data Analytic "has gained Indivumed extensive knowledge of oncology cohorts, and even of individual patients, providing a unique and in-depth insight into cancer biology.
Indivumed through this joint venture significantly expands its offer. With state-of-the-art high-quality biobank products and laboratory services provided by IndivuServ or the most comprehensive multi-omics oncology database available today, and the high knowledge of target work and discovery and biomarkers offered by IndivuType, Ix Therapeutics is an evolutionary step in the history of the company, which enters the pharmaceutical development sector.
"Indivumed's IndivuType database fascinates us, as does its effectiveness in discovering goals," said Oliver R. Baumann , CEO of Xlife Sciences. against cancer and we are proud to be part of this groundbreaking success. "
Indivumed will explore several new goals that Ix Therapeutic will focus exclusively on in the development of functional therapeutic antibodies created using Veraxa microfluidic droplet technology.
